Top

FDA approves next-gen MitraClip from Abbott

July 12, 2018

Abbott (NYSE:ABT) won FDA approval for the third generation of its MitraClip transcatheter heart valve repair device, the company said today.

Acquired in the $410 million acquisition of Evalve back in 2009, MitraClip won its first FDA nod in 2013. Abbott said today that the latest iteration won CE Mark approval in the European Union earlier this year. The new version upgrades MitraClip’s steering, navigation and positioning capabilities and a second clip size with expanded reach, the Chicago-area healthcare giant said.

Read More on Mass Device